

Supplementary Figure 1: Memory phenotype of peripheral blood γδ T cells populations. A and B. Representative flow cytometry plots and graphs show CD27 and CD45RAT cell memory marker expression on gated populations of CD3⁺ $\alpha\beta^{neg}$ $\gamma\delta$ T cells: V $\delta2^+$, V $\delta2^{neg}$ and V $\delta1^+$ T cells. Flow cytometry plots are from one donor and are representative of the graphed data, n=18.



Diverse Võ1⁺ T cell Repertoire

F



Supplementary Figure 2: Clonotypic focussing in the V δ 1⁺ T cell compartment. A. Comparison of total sequencing reads against the number of unique CDR3s determined for each donor, n=25 (left) and the mean ±SEM of total sequencing reads for each donor grouping (right), focussed (n=13), diverse (n=7) and cord blood (n=5). Data analysed by one-way ANOVA. B. Correlation of V γ 9 frequency in V δ 1⁺ T cells obtained by TCR-repertoire sequencing and flow cytometry for each donor (n=20). C. Grouped V γ chain usage in V δ 1+ TCR repertoire sequencing for each donor, focussed (n=13), diverse (n=7), and cord blood (n=5) donors. Data were analysed by Kruskal-Wallis ANOVA with Dunn's post-test comparisons,

* P<0.05, ** P<0.01 and *** P<0.001. **D.** V γ chain usage by V δ 1⁺ T cells from remaining donors not

shown in Fig. 2. **E** and **F**. Additional data from adult focussed (**E**), and adult diverse and cord (**F**) donor groupings. These show tree maps of CDR3 γ and δ clonotype usage in relation to repertoire size (each CDR3 colour is chosen randomly and does not match between plots) and graphs showing the individual clone frequency (left y-axis) and the accumulated frequency for the first 10 most prevalent clonotypes (right y-axis), for the donors not shown in Fig 2B, E and Fig 3E.



Supplementary Figure 3: $\gamma\delta$ **TCR repertoire analysis of adult V** $\delta2^{neg}$ $\gamma\delta$ **T cells. A.** V γ and V δ chain usage in V $\delta2^{neg}$ TCR repertoire data from 4 individuals. **B.** Tree maps showing CDR3 clonotype usage in the V $\delta2^{neg}$ $\gamma\delta$ subset in relation to repertoire size and graphs show individual clone frequency against accumulated frequency for the top 10 most prevalent clonotypes. Data are representative of 4 individuals. **C.** Accumulated frequency plots for V $\delta3$ and V $\delta8$ clonotypes detected within the V $\delta2^{neg}$ $\gamma\delta$ repertoire (left and middle) and a comparison frequency of the top 10 clones in each of V $\delta1$, V $\delta3$, V $\delta8$ filtered repertoires (right). Data are from 2 different donors.



Supplementary Figure 4: CDR3δ1 diversity in CMV⁺ and CMV^{neg} **donors.** Box plots show mean ±SD of the Shannon-Wiener index of CDR3δ1 diversity in CMV-seronegative (n=10) and CMV-seropositive (n=10) donor TCR repertoires, with differences between groups measured by students t-test, but not significant; p= 0.15.



В

IMGT Junction analysis of well-represented extra-long TRDV1-TRDJ1 CDR3 sequences

| Donor | Reads, | Reads, | CDR3 nucleotide sequence: V-Region N-insertions P-insertions TRDD1 TRDD2 TRDD3 I-Region | Length, | N/P |
|-------|--------|--------|------------------------------------------------------------------------------------------------------------------------------------|---------|-----|
| | count | % | | nt | nt |
| 6 | 32 | 0.048% | TGTGCTCTTGGGGAAC <mark>GGGTCGCGCTCCGGCGGT</mark> CTTCCAAGGAT <mark>TCTGGGGGATACC</mark> ACGGAGGT <mark>ACACCGATAAACTCATCTTT</mark> | 87 | 33 |
| 30 | 88 | 0.115% | TGTGCTCTTGGGGAATGCCCCCCCCTACTCTTGTCTCAAGCACAACTTGATCTGGGGGATACCCCCCGGGGAATTAGC <mark>TAAACTCATCTTT</mark> | 90 | 45 |
| 31 | 193 | 0.076% | TGTGCTCTTGGGGAAAGAAGATTCCTAATGGTGGACTTCTTTGGGGGGAAAACTGGGGGGAAAACCGGACGACGATAAACTCATCTTT | 90 | 40 |
| 38 | 185 | 0.109% | TGTGCTCTTGGGGAACCCCCCCAGAGATTACGC <mark>TGGGGGGATAC</mark> TCAAAGAAGTTCATCCAGAGGGCCCAGGGGGGCTGT <mark>ACACCGATAAACTCATCTTT</mark> | 99 | 52 |
| 32 | 60 | 0.050% | TGTGCTCTTGGGGAAGTCCCTGCCTGCCTGGCCCGAGGATAAGAGGATGT <mark>TGGGGGA</mark> GACATACTCCCAC <mark>TACACCGATAAACTCATCTTT</mark> | 93 | 45 |
| 11 | 19 | 0.047% | TGTGCTCTTGGGGAACTAAACTGGCAGATACACCTTCCTACGTGGCGGGGGCCGGGGGGATACGGGCCTTTCGGGTACACCGATAAACTCATCTT | 93 | 37 |

Supplementary Figure 5: CDR361 contain rare, unusually long functional sequences. A. Selected normalised spectratypes from two donors with notable extra-long CDR3 variants, shown with red circles, representative of 6 individuals. **B.** Selected well-represented extra-long TRDV1-TRDJ1 CDR3 sequences, showing actual read count in raw repertoire sequencing, % of total sequencing reads, overall length of CDR3 region (nt) and total N/P nucleotide addition in each sequence.



Α

TRDV2

TRDV1

Color Key

Supplementary Figure 6: TCRy characteristics for Võ1⁺ and Võ2⁺ yõ T cells. A. Normalised Vy gene segment usage in Võ1⁺ and Võ2⁺ yõ TCR repertoires. **B.** 3D representation of typical Vy-Jy gene segment usage in Võ2⁺ (top row; showing 3 representative donors out of 4) and Võ1⁺ (bottom row; showing 3 representative donors out of 20) yõ T cells, calculated per sequencing read (non-normalised). **C.** Length distribution and mean (red line) of the top 10 most prevalent clonotypes in CDR3õ (bottom left) and CDR3 γ (bottom right) from indicated Võ1⁺ T cell donors not shown in Fig 4D. **D.** Jensen-Shannon divergence between non-normalised TCR γ repertoires in Võ1⁺ and Võ2⁺ subsets based on the CDR3 amino acid sequence length, 2D representation of multidimensional clustering (VDJ Tools software).



| Donor 3 | % | Donor 6 | % | Donor 7 | % | Donor 41 | % | Cord blood 4 | % |
|----------------------|------|---------------------|------|------------------|------|-------------------|------|------------------|------|
| CALWEVQELGKKIKVF | 15.1 | CALWETQELGKKIKVF | 22.9 | CALWEVQELGKKIKVF | 13.0 | CALWEVQELGKKIKVF | 17.7 | CALWEVQELGKKIKVF | 15.2 |
| CALWEAQELGKKIKVF | 8.9 | CALWEVRKELGKKIKVF | 18.5 | CALWEAQELGKKIKVF | 10.5 | CALWEVRELGKKIKVF | 6.3 | CALWEQELGKKIKVF | 2.7 |
| CATWDGGYYKKLF | 5.9 | CALWEVQELGKKIKVF | 6.6 | CALWEVRELGKKIKVF | 4.9 | CALWEVFELGKKIKVF | 5.5 | CALWEVRELGKKIKVF | 2.4 |
| CALWEVRELGKKIKVF | 3.2 | CALWEVRELGKKIKVF | 3.9 | CASPELFYYKKLF | 3.8 | CALWEAGVLGKKIKVF | 3.4 | CATWDTTGWFKIF | 1.5 |
| CALWEGKQELGKKIKVF | 2.1 | CALWEVLSPQELGKKIKVF | 3.4 | CALWEVKELGKKIKVF | 2.4 | CALWEAQELGKKIKVF | 2.4 | CALWEAQELGKKIKVF | 1.0 |
| CALWEQELGKKIKVF | 1.8 | CALWEQELGKKIKVF | 3.0 | CALWQELGKKIKVF | 1.8 | CALWEVLELGKKIKVF | 1.7 | CALWEVELGKKIKVF | 0.9 |
| CALWTAQELGKKIKVF | 1.7 | CALWEVQGLGKKIKVF | 2.3 | CALWEVGELGKKIKVF | 1.6 | CALWSTELGKKIKVF | 1.6 | CALWEEELGKKIKVF | 0.8 |
| CALWEVHPGVFELGKKIKVF | 1.4 | CALWEVLELGKKIKVF | 2.1 | CALWEVLELGKKIKVF | 1.4 | CALWEVPELGKKIKVF | 1.6 | CALWEVLELGKKIKVF | 0.8 |
| CALWETSWELGKKIKVF | 1.4 | CALWENPKLGKKIKVF | 2.0 | CALWEVHELGKKIKVF | 1.2 | CALWEVHRELGKKIKVF | 1.6 | CATWDRNYYKKLF | 0.8 |
| CALWEEELGKKIKVF | 1.4 | CALWEVEELGKKIKVF | 1.7 | CALWEVEELGKKIKVF | 1.2 | CALWEQELGKKIKVF | 1.3 | CALWELGKKIKVF | 0.8 |



Supplementary Figure 7: Public V γ 9 sequences from V δ 2⁺ $\gamma\delta$ T cells. A and B. Analysis of frequency (A) and sequence identity (B) of CDR3 γ sequences from sorted V δ 2⁺ $\gamma\delta$ T cells from four healthy adult donors and one cord blood. C and D. Visual representation of amino acid enrichment at each position of CDR3 γ (C) and CDR3 δ (D) sequences from V δ 2⁺ $\gamma\delta$ T cells. Analysis was confined to the 20 most abundant CDR3 γ of 14 amino acids from each of 4 adult donors, or ten most abundant CDR3 δ 2 sequences using V δ 2-J δ 1 of 13-15 amino acids length.



Supplementary Figure 8: Gating strategy for identifying and sorting T cells. A. Representative flow cytometry plots show the gating strategy used to identify single/live/lymphocytes and CD3⁺ TCR $\alpha\beta^{neg}$ T cells. **B** and **C**. Using the gating strategy in **A**., Vδ1⁺ and Vδ2⁺ (**B**) and Vδ2^{neg} γδ T cells (**C**) were sorted with TCR specific antibodies from CD3⁺ TCR $\alpha\beta^{neg}$ T cells. **D**. CD8⁺ $\alpha\beta$ T cells were identified by gating single/live/lymphocytes and CD3⁺ T cells (as shown in **A**.), selecting TCR Vδ1/Vδ2^{neg} cells and gating CD8⁺ T cells (left). CD27 and CD45RA were used to define memory T cell populations (Naïve, central memory; CM, effector memory; EM and effector memory CD45RA-revertants; EMRA) within CD8⁺ $\alpha\beta$ T cells (right). Flow cytometry plots are representative of 20 donors.

| Donor | TCR | Sequencing | Total | Unique | Cell Numbers |
|-----------|-------|------------------|------------------|--------|---------------------|
| | Chain | Reads | CDR3 | CDR3 | (x 10 ³⁾ |
| 3 | TRD | 247354 | 215495 | 936 | 25 |
| | TRG | 489350 | 420583 | 657 | 25 |
| 5 | TRD | 301692 | 270866 | 1042 | 7.6 |
| | TRG | 249187 | 227705 | 643 | 7.6 |
| 6 | TRD | 188791 | 161794 | 359 | 7.2 |
| | TRG | 294125 | 284516 | 289 | 7.2 |
| 7 | TRD | 164806 | 140173 | 2650 | 25 |
| | TRG | 455352 | 396695 | 1789 | 25 |
| 11 | TRD | 193606 | 175261 | 936 | 25 |
| | TRG | 227924 | 208569 | 372 | 25 |
| 15 | TRD | 324650 | 308838 | 1676 | 25 |
| | TRG | 267362 | 260771 | 780 | 25 |
| 20 | TRD | 395517 | 371202 | 2051 | 25 |
| | TRG | 437885 | 415557 | 816 | 25 |
| 22 | TRD | 143487 | 142436 | 684 | 25 |
| | TRG | 389641 | 342630 | 390 | 25 |
| 26 | TRD | 359679 | 349164 | 7004 | 25 |
| | TRG | 562324 | 536932 | 3023 | 25 |
| 27 | TRD | 481992 | 457103 | 5443 | 25 |
| | TRG | 687234 | 635982 | 2826 | 25 |
| 28 | TRD | 110158 | 102974 | 2230 | 25 |
| 20 | TRG | 125384 | 107150 | 563 | 25 |
| 29 | | 288125 | 266648 | 1985 | 25 |
| 23 | TRG | 611184 | 5000-58 | 1105 | 25 |
| 31 | | 375423 | 350112 | 2253 | 25 |
| 01 | TRG | 660044 | 645027 | 1356 | 25 |
| 32 | | 140130 | 134080 | 1330 | 25 |
| 52 | TRC | 463030 | 134000 | 028 | 25 |
| 33 | | 366003 | 355460 | 2804 | 25 |
| | TRC | 3/1720 | 308335 | 1273 | 25 |
| 34 | | 402725 | 354764 | 1156 | 25 |
| | TRG | 430176 | 403286 | 587 | 25 |
| 35 | | 285454 | 284410 | 717 | 25 |
| | TRC | 500028 | 563321 | / 17 | 25 |
| 36 | | 370710 | 350/88 | 10111 | 25 |
| | TRC | 3/6823 | 300217 | 33/1 | 25 |
| 37 | | 414550 | 385585 | 3763 | 25 |
| 51 | TRD | 21/117 | 195311 | 1522 | 25 |
| 38 | TRG | 1/78/1 | 131060 | 1022 | 25 |
| | | /201/2 | 305512 | 5140 | 25 |
| 30 | TRC | 186273 | 1706/3 | 2758 | 25 |
| | | 366753 | 345628 | 7117 | 25 |
| 11 | TPC | 538556 | 47020 | 804 | 25 |
| 41 | | 655818 | 636010 | 1665 | 25 |
| CR01 | | 122686 | 10/065 | 2240 | 7 1 |
| CBUT | TRD | 252078 | 225747 | 1662 | 7.1 |
| CB03 | | 202010 | 25/017 | 1602 | 1.1 11 <i>1</i> |
| 0005 | TRD | 205021 | 199294 | 2085 | 11.4 |
| CR04 | | 200191 | 284040 | 2005 | 25 |
| 0004 | TRD | 19157/ | 157254 | 3467 | 25 |
| CP05 | | 202495 | 100204 | 020 | 25 |
| 0605 | | 203403 | 226726 | 920 | 7 |
| CROS | | 500000 | J20120 | 1027 | |
| | | 183212 | 430032 | 3/22 | 5.2 |
| | | 703213 | +/ 1// 1 | 3433 | 0.2 |
| 21 CD276 | TPC | 157510 | /17079 | 1010 | E |
| 31-002/11 | | 407010 570504 | 41/9/0 EE0276 | 1010 | 5 |
| 21 002710 | | 019091 | 003010 | 2004 | 5 |
| 31-002/10 | | 04284U | 0203/0 | 230 | 0.2 |
| 20.0025 | | 07001U 426066 | 000050 | 304 | 0.2 |
| 29-CD2/11 | | 430800 | 409059 | 1425 | 4 |
| 20.00071- | | 501509 | 4/005/ | 3492 | 4 |
| 29-002/10 | | 597053 | 05024 | 229 | 6 |
| | IKU | 008010 | 495834 | 118 | р |

Supplementary Table 1: Details of raw sequencing data. The table displays each sample's analysed total sequencing reads, total CDR3 assigned, unique CDR3 identified and the number of cells obtained per sample.

| germline | | TRGV | N/P | TRGJ | | | | | | |
|----------------------|---------------------------|-------------------------------------------------------------------|--------------|----------------------------------------------------------------------------------------------------------|----------------------------|--------------------|---------------|--------|--------|-----------|
| | TRGV2 TRGV3/5 TRGV4 | GCC ACC TGG GAC GGG GCC ACC TGG GAC AGG GCC ACC TGG GAT GGG | | G AAT TAT TAT AAG AAA CTC T GGG CAA GAG TTG GGC AAA AAA ATC AAG GTA AT ACC ACT GGT TGG TTC AAG ATA | TRGJ1/2 TRGJP TRGJP1 | | | | | |
| | TRGV8 TRGV9 | GCC ACC TGG GAT AGG GCC TTG TGG GAG GTG | | AT AGT AGT GAT TGG ATC AAG ACG | TRGJP2 | CDR3 | N/P | CMV | EBV | |
| clone POS4 LES | TRGV8 TRGV4 | GCC ACC TGG GAT A GCC ACC TGG GAT GG | ATT | CC ACT GGT TGG TTC AAG ATA T TAT AAG AAA CTC | TRGJP1 TRGJ1/2 | length 33 33 | nts 0 3 | status | status | D75 |
| donor | | | | | | | | | | |
| 29 | TRGV2 | GCC ACC TGG GAC GG | ATCC | TAT TAT AAG AAA CTC | TRGJ1/2 | 33 | 4 | , | + | 0.25 |
| 37 | TRGV2 | GCC ACC TGG GAC G | CCCTCGGG | TAT TAT AAG AAA CTC | TRGJ1/2 | 36 | 8 | + | , | 13.40 |
| 7 | TRGV3 | GCC ACC TGG GAC AGG | CGACCCAA | T AGT GAT TGG ATC AAG ACG | TRGJP2 | 42 | 8 | , | + | 16.00 |
| 28 | TRGV3 | GCC ACC TGG GAC AGG | ATTT | T TAT AAG AAA CTC | TRGJ1/2 | 33 | 5 | , | + | 1.47 |
| 39 | TRGV3 | GCC ACC TGG GAC AGG | CCTG | AG AAA CTC | TRGJ1/2 | 27 | 4 | + | + | 28.80 |
| 27 | TRGV4 | GCC ACC TGG GAT GGG | CGTGAGGG | T TAT AAG AAA CTC | TRGJ1/2 | 36 | 8 | + | + | 11.73 |
| 9 | TRGV5 | GCC ACC TGG | TCCTGGTAGG | G AAA CTC | TRGJ1/2 | 27 | 1 | + | + | 2.30 |
| 31 | TRGV5 | GCC ACC TGG G | TAC | AT AAG AAA CTC | TRGJ1/2 | 24 | £ | + | , | 0.12 |
| £ | TRGV9 | GCC TTG TGG G | GAAACCT | T TAT TAT AAG AAA CTC | TRGJ1/2 | 33 | 7 | + | + | 1.23 |
| 5 | TRGV9 | GCC TTG TGG GAG | CGGGG | G TTG GGC AAA AAA ATC AAG GTA | TRGJP | 39 | 5 | + | + | 3.79 |
| 11 | TRGV9 | GCC TTG T | CTCAGCGGTCC | AAT TAT TAT AAG AAA CTC | TRGJ1/2 | 36 | 11 | , | + | 8.24 |
| 15 | TRGV9 | GCC TTG TGG | AGCCACCC | T TAT TAT AAG AAA CTC | TRGJ1/2 | 33 | 8 | + | + | 2.78 |
| 22 | TRGV9 | GCC TTG TGG GAG GTG | 9000000 | AT TAT AAG AAA CTC | TRGJ1/2 | 36 | 7 | , | + | 0.14 |
| 32 | TRGV9 | GCC TTG TGG GAG GTG | | TAT TAT AAG AAA CTC | TRGJ1/2 | 30 | 0 | , | + | 0.07 |
| 33 | TRGV9 | GCC TTG TGG GAG GTG | CAA | ACT GGT TGG TTC AAG ATA | TRGJP1 | 36 | e | | + | 1.87 |
| 34 | TRGV9 | GCC TTG TGG GAG G | ACTCG | TAT TAT AAG AAA CTC | TRGJ1/2 | 33 | 5 | + | + | 0.30 |
| 35 | TRGV9 | GCC TTG TGG GAG GTG C | CATATTGGA TC | G AAT TAT TAT AAG AAA CTC | TRGJ1/2 | 45 | 11 | + | + | 0.11 |
| 36 | TRGV9 | GCC TTG T | CCCCTTC | T AAG AAA CTC | TRGJ1/2 | 24 | 7 | | , | 27.21 |
| 38 | TRGV9 | GCC TTG TGG GAG G | ט | G AAT TAT TAT AAG AAA CTC | TRGJ1/2 | 33 | - | , | + | 25.51 |
| 41 | TRGV9 | GCC TTG TGG GA | | T TAT TAT AAG AAA CTC | TRGJ1/2 | 27 | 0 | | , | 9.18 |
| | | | | | ODETOVE | 33 15 | 8 2 | | | |
| | | | | | rande | 24-45 | 0-11 | | | |
| | | | | | - AL | 6 | - | | | |
| upplement | ary Ta | ble 2: Prevalent C | DR3V se | equences are private. The most pre | evalent | TCRV | clon | otype | sequ | ence from |
| | | | | | | | | | | |

each adult donor is shown. Vy and Jy gene segments used are indicated, and N and P nucleotides are shown in red and blue, respectively. The CDR3y length, number of N/P nucleotides, CMV/EBV status, and TCRy diversity (D75) of each donor is shown. S

| | D75 | 1.32 3.88 | 3.14 | 9.86 | 5.12 | 0.12 | 4.02 | 5.12 | 1.33 | 0.38 | 0.82 | 3.25 | 0.41 | 0.11 | 24.6 | 11.6 | 17 | 24.2 | 14.5 | | | |
|--------------------------------------------------------------------------|---------------------------------------------------|--------------------------------------------------|------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|------------------------------|---------------------------|-------------------------|-------------------------|----------------------------------|--------------------------|-------------------------|-----------------------------|-------------------------|--------------------------|---------------------|------------------------------|-----------------------------|------------------------------|---------|---------|---------|
| ERV | status | + + | + | + + | + | + | + | + | + | | + | + | + | + | , | , | + | + | , | | | |
| | status | + + | + | | + | | + | | , | + | | , | + | + | | + | | + | , | | | |
| 0/N | nts 0 14 | 16 11 | 17 | 16 | 19 | 20 | 10 | 23 | 12 | 13 | 14 | 5 | 14 | 14 | 5 | 19 | 25 | 19 | 20 | 15.5 | 5-25nt | 1107 0 |
| | length 33 48 | 60 42 | 57 | 57 45 | 45 | 60 | 42 | 60 | 54 | 57 | 51 | 33 | 57 | 45 | 27 | 51 | 69 | 60 | 60 | 516 | +u09-2C | 11/0 /7 |
| IRDJ AC ACC GAT AAA CTC ATC TRJD1 CT TTG ACA GCA CAA CTC TTC TRJD2 | GAT AAA CTC ATC TRJD1 CC GAT AAA CTC ATC TRJD1 | ACC GAT AAA CTC ATC TRJD1 A CTC ATC TRJD1 | AC ACC GAT AAA CTC ATC TRJD1 | al all date of the art of the true of the | C ACC GAT AAA CTC ATC TRJD1 | AC ACC GAT AAA CTC ATC TRJD1 | ACC GAT AAA CTC ATC TRJD1 | C GAT AAA CTC ATC TRJD1 | GAT AAA CTC ATC TRJD1 | CT TTG ACA GCA CAA CTC TTC TRJD2 | CC GAT AAA CTC ATC TRJD1 | CTC ATC TRJD1 | C ACC GAT AAA CTC ATC TRJD1 | C GAT AAA CTC ATC TRJD1 | AA CTC ATC TRJD1 | T AAA CTC ATC TRJD1 | AC ACC GAT AAA CTC ATC TRJD1 | C ACC GAT AAA CTC ATC TRJD1 | AC ACC GAT AAA CTC ATC TRJD1 | enerene | | 101 C |
| d/N | TACAGGGT | TAGGGGGA AGCC | CCAGTACTTCATA | GAAGGGGIGIGI TCAAG | CGCTGCCTGT | CCACC | U U | CTCAG | | GATCTCC | TTCG | TCGAG | | CCCA | | TTCAGG | TGGCGCATCGTCCCCAACTC GT | ACCCCCG | AAACGT | | | |
| TRDD3 ACTGGGGGGATACG | GGGGGAT GGGGGATA | ACTGGGGGGATAC ACTGGGGGGATAC | CTGGGGGGATACG | ALACG | | ACTGGG | TGGGGGGATACG | ACTGGGGG | ACTGGGGGGATACG | ACT GGGGG | ACTGGG | CTGGGGGGAT | GGGATACG | TGGGG | | GGGGGGATA | ACTGGGGGGATAC | CTGGGGGGATAC | ACTGGG | | | |
| N/P | ЧЦ | CTCATC GT | I | 5 | ט | GATGGAG | | GTT | ATACCGTT GT | CCGT | TAC | | GA | | | AAGGGTC | | | ACT | | | |
| TRDD2 CCTTCCTAC | CCTA | CTAC | | CLICC | CCTAC | TTCCTA | | CCTAC | TTCC | TCCT | CCTTCCTA | | TTCCTAC | | | CCTTC | TTCC | | CCTTCCTA | | | |
| N/P TRDD1 GAAATAGT | Ţ | GTGCGAT | CCTC | CGG TAAAACGGGGGT | CCAACCCC | CGCAGATT | ATCTCACT | CACCCGGCCTCCGAG | AT | Α | TTGCC GG | | AGGCGGATCGCA | CCGGAGGCCT | CGGAG | ACTCCC | TCTA | GGTCATCGGACC | AACCCGGGGAGA | | | |
| TRDV TRDV1 GCT CTT GGG GAA CT \\\29/DV5 GCA GCA AGC G | TRDV1 GCT CTT GGG GAA CT TRDV5 GCA GCA AGC | TRDV1 GCT CTT GGG GAA C TRDV1 GCT CTT GGG GAA | TRDV1 GCT CTT GGG GA | TRDVI GCT CTT GGG G | TRDV1 GCT CT | TRDV1 GCT CTT GGG GA | TRDV1 GCT CTT | TRDV1 GCT CTT GGG GA | TRDV1 GCT CTT GGG GAA C | TRDV1 GCT CTT GGG GAA C | TRDV1 GCT CTT GGG | TRDV1 GCT CTT GGG GAA C | TRDV1 GCT CTT GGG GAA | TRDV1 GCT CTT GGG GAA C | TRDV1 GCT CTT GGG GAA CT | TRDV1 GCT CTT GGG | TRDV1 GCT CTT GGG GA | TRDV1 GCT CTT GGG GAA CT | TRDV1 GCT CTT GGG | | | |
| germline TRA | clone POS4 LES | donor 3 5 | 9 | - 1 | 15 | 22 | 27 | 28 | 29 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 41 | | | |

sequence from each adult donor. Sequences were analysed using IMGT Junction Analysis, which identified V, D, and J gene segments used, and highlighted N (red) and P (blue) nucleotides. The CDR301 length, number of N/P nucleotides, CMV/EBV status of each donor, and TCR0 diversity (D75) is shown. Supplementary Table 3: Prevalent CDR301 sequences are complex and private. The most prevalent TCR01 clonotype

| germline | TRGV | | CDR3γ | TRGJ | | | | |
|----------|---------|--------|-------|-------------|--------------|------------|--------|--------|
| - | | | | NYYKKLF | TRGJ1/2 | | | |
| | TRGV2-8 | CATWDG | | GQELGKKIKVF | TRGJP*01 | | | |
| | TRGV9 | CALWEV | | TTGWFKIF | TRGJP1*01 | | | |
| | | | | SSDWIKTF | TRGJP2*01 | | | |
| | | | | | | CDR3 | CMV | EBV |
| clone | | | | | | length(aa) | status | status |
| POS4 | TRGV8 | CATWD | | TTGWFKIF | TRGJP1*01 | 11 | + | ? |
| LES | TRGV4 | CATWDG | F | YYKKLF | TRGJ1/2 | 11 | + | ? |
| | | | | | | | | |
| donor | | | | | | | | |
| 29 | TRGV2 | CATWDG | S | YYKKLF | TRGJ1/2 | 11 | - | + |
| 37 | TRGV2 | CATWD | ALG | YYKKLF | TRGJ1/2 | 12 | + | - |
| 7 | TRGV3 | CATWD | RRPN | SDWIKTF | TRGJP2*01 | 14 | - | + |
| 28 | TRGV3 | CATWD | RIF | YKKLF | TRGJ1/2 | 11 | - | + |
| 39 | TRGV3 | CATWD | RPE | KLF | TRGJ1/2 | 9 | + | + |
| 27 | TRGV4 | CATWDG | REG | YKKLF | TRGJ1/2 | 12 | + | + |
| 6 | TRGV5 | CATW | FLVG | KLF | TRGJ1/2 | 9 | + | + |
| 31 | TRGV5 | CATW | VH | KKLF | TRGJ1/2 | 8 | + | - |
| 3 | TRGV9 | CALW | GNL | YYKKLF | TRGJ1/2 | 11 | + | + |
| 5 | TRGV9 | CALWE | RG | LGKKIKVF | TRGJP*01 | 13 | + | + |
| 11 | TRGV9 | CAL | SQRS | NYYKKLF | TRGJ1/2 | 12 | - | + |
| 15 | TRGV9 | CALW | SHP | YYKKLF | TRGJ1/2 | 11 | + | + |
| 22 | TRGV9 | CALWEV | AGH | YKKLF | TRGJ1/2 | 12 | - | + |
| 32 | TRGV9 | CALWEV | | YYKKLF | TRGJ1/2 | 10 | - | + |
| 33 | TRGV9 | CALWEV | Q | TGWFKIF | TRGJP1*01 | 12 | - | + |
| 34 | TRGV9 | CALWE | DS | YYKKLF | TRGJ1/2 | 11 | + | + |
| 35 | TRGV9 | CALWEV | HIGS | NYYKKLF | TRGJ1/2 | 15 | + | + |
| 36 | TRGV9 | CAL | SPS | KKLF | TRGJ1/2 | 8 | - | - |
| 38 | TRGV9 | CALWE | GNL | NYYKKLF | TRGJ1/2 | 11 | - | + |
| 41 | TRGV9 | CALW | D | YYKKLF | TRGJ1/2 | 9 | - | - |
| | | | | | average (aa) | 11.05 | | |
| | | | | | range | 8-15aa | | |

Supplementary Table 4: Prevalent CDR3y sequences are private. The most prevalent TCRy clonotype sequence from each adult donor. Sequences were analysed using IMGT Junction Analysis, which identified V, D, and J gene segments used. The CDR3y length, and CMV/EBV status of each donor is shown.

| germline | | TRDV | CDR3δ | TRDJ | | | | |
|----------|-------|-------|-----------------|-----------|---------|------------|--------|--------|
| | | | | TDKLIF | TRDJ1 | | | |
| | TRDV1 | CALGE | | LTAQLFF | TRDJ2 | | | |
| | TRDV5 | CAAS | | SWDTRQMFF | TRDJ3 | | | |
| | | | | RPLIF | TRDJ4 | | | |
| | | | | | | CDR3 | CMV | EBV |
| clone | | | | | | length(aa) | status | status |
| POS4 | TRDV1 | CALGE | LGD | DKLIF | TRJD1 | 11 | + | ? |
| LES | TRDV5 | CAAS | SPIRGYTGS | DKLIF | TRJD1 | 16 | + | ? |
| | | | | | | | | |
| donor | | | | | | | | |
| 3 | TRDV1 | CALGE | PTSSYWGILGG | TDKLIF | TRJD1 | 20 | + | + |
| 5 | TRDV1 | CALGE | VRYWGIQP | LIF | TRJD1 | 14 | + | + |
| 6 | TRDV1 | CALG | DLLGDTPVLHN | TDKLIF | TRJD1 | 19 | + | + |
| 7 | TRDV1 | CALG | DGLPYTEGVLY | TDKLIF | TRJD1 | 19 | - | + |
| 11 | TRDV1 | CALG | VKRGLGDTQE | LIF | TRJD1 | 15 | - | + |
| 15 | TRDV1 | CAL | QPPYALPV | TDKLIF | TRJD1 | 15 | + | + |
| 22 | TRDV1 | CALG | DADFPRWRLGHH | TDKLIF | TRJD1 | 20 | - | + |
| 27 | TRDV1 | CAL | ISLGGYA | TDKLIF | TRJD1 | 14 | + | + |
| 28 | TRDV1 | CALG | DTRPPSLRYWGLS | DKLIF | TRJD1 | 20 | - | + |
| 29 | TRDV1 | CALGE | HFHTVVLGD | TDKLIF | TRJD1 | 18 | - | + |
| 31 | TRDV1 | CALGE | HPPYWGDLP | LTAQLFF | TRJD2 | 19 | + | - |
| 32 | TRDV1 | CALG | LPAFLYTGFA | DKLIF | TRJD1 | 17 | - | + |
| 33 | TRDV1 | CALGE | PGGFE | LIF | TRJD1 | 11 | - | + |
| 34 | TRDV1 | CALGE | RRIAFLRGIR | TDKLIF | TRJD1 | 19 | + | + |
| 35 | TRDV1 | CALGE | PGGLGAH | DKLIF | TRJD1 | 15 | + | + |
| 36 | TRDV1 | CALGE | LGE | LIF | TRJD1 | 9 | - | - |
| 37 | TRDV1 | CALG | TPPSRVGGYSG | KLIF | TRJD1 | 17 | + | - |
| 38 | TRDV1 | CALG | DLFHWGILAHRPNSY | TDKLIF | TRJD1 | 23 | - | + |
| 39 | TRDV1 | CALGE | LVIGPWGIHPR | TDKLIF | TRJD1 | 20 | + | + |
| 41 | TRDV1 | CALG | NPGDLPNYWETY | TDKLIF | TRJD1 | 20 | - | - |
| | | | | | | | | |
| | | | | | average | 17.2 | | |
| | | | | | range | 9-23aa | | |

Supplementary Table 5: Prevalent CDR3δ1 sequences are complex and private. The most prevalent TCRδ1 clonotype sequence from each adult donor. Sequences were analysed using IMGT Junction Analysis, which identified V, D, and J gene segments used. The CDR3δ1 length (amino acids), and CMV/EBV status of each donor is shown